NCT06524544View on ClinicalTrials.gov

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Sacituzumab Govitecan Alone in the Treatment of Advanced Urothelial Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Locally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Sacituzumab Govitecan

Given IV

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH